Board of Directors

The Board of Directors is responsible for Genovis’ long-term operations and the organization of the company.

Genovis’ Board consists of seven members elected by the AGM. The Board meets five times a year according to the schedule adopted by the Board. In addition to regular meetings, the Board may also be convened as necessary.

Member of the Board of Directors since: 2019
Born: 1968
Education: MSc, PhD
Shares in Genovis: None

Other Directorship

Chairman of the board of Directors in Edvince AB and BumleFish AB. Member of the Board of Directors in Sweden Bio, Respiratorius AB, SwedNanoTech AB och LU Holding AB.

Relevant Work Experience

Sarah Fredriksson is the CEO of Aqilion AB, a Swedish life science company that starts, develops and sells pharmaceutical projects at an early phase in the drug discovery process. Sarah is the founder of Genovis and was the company’s CEO until 2015, after which she was chairperson of the board until 2016. She has published several scientific articles, authored several patent applications and has extensive experience in laboratory work in the sector for which Genovis’ products are mainly intended. In 2016 she was a finalist in the EU Prize for Women Innovators for her work at Genovis.

Independency: Independent in relation to the company, its management and the company’s major shareholders.

Last updated: February 11, 2020

Member of the board since: 2018
Born: 1960
Education: BSc in Medical Science and Executive MBA
Shares in Genovis: None

Other Directorship

Board member of Uppsala universitet Holding AB, SLU Holding AB, Bio-Works AB, Dicot AB and member of the Chamber Council at Stockholm Chamber of Commerce.

Relevant Work Experience

Lena Söderström has 30 years' experience in management positions in international pharmaceutical companies and in the medical device industry. Positions e.g. people management, project management, business development, international marketing and manufacturing.

Independency: Independent in relation to the company, its management and the company’s major shareholders.

Last updated: January 10, 2019

Member of the board since: 2014
Born: 1949
Education: MD
Shares in Genovis: Holds 9,990,653 shares

Other Directorship

Board member of LOX Container Technology AB, PRIMA Barn- och Vuxenpsykiatri Holding AB, PRIMA Barn- och Vuxenpsykiatri Stockholm AB, Vizendo AB, Dicel AB, Sturebadet Health AB, Redeye AB/Redhold AB, Mikael Lönn AB, Professionell ägarstyrning i Sverige AB, Professionell ägarstyrning PÄAB ll, Skogsägarna Mellanskog Ekonomisk förening, Ilya Pharma AB and Spago Nanomedical AB.

Relevant Work Experience

Mikael Lönn is a physician, entrepreneur and has been active as business leader, mainly in the health care sector. He has extensive experience of financial investments, providing consultancy services and participated on the board of directors for a number of startup and growth companies, as well as experience from large county council and municipal-owned organi­zations.

Independency: Independent in relation to the company’s management and its major shareholders but not in relation to the company.

Last updated: November 1, 2019

Member of the board since: 2011
Born: 1956
Education: BA
Shares in Genovis: 49,998

Other Directorship

Chairman of the board of Directors in AlphaBeta AB, Biocrine AB, Spiber Technologies AB and Science Pacific AB. Member of the Board of Directors in Alligator Bioscience AB.

Relevant Work Experience

Kenth Petersson has previously worked as an analyst and has extensive experience in the biotech industry. For the past 10 years he has worked as a business angel and principal owner of a number of biotech companies.

Independency: Independent in relation to the company, its management and the company’s major shareholders.

Last updated: February 15, 2019

Member of the board since: 2018
Born: 1957
Education: Master of Science in Business and Economics
Shares in Genovis: None

Other Directorship

Board member of Lacolle AB, Savelend Credit Group AB and other companies within the Savelend Group and Billecta AB and other companies within the Billecta Group.

Relevant Work Experience

Peter Hein has extensive experience from leading positions in the life science industry. He has been CFO at Q-Med and Biolipox (Orexo). He has also served as CFO and CEO of Granngården and is currently working as a consultant and interim CFO for a couple of small biotech companies. His background is in business and finance, among others from Ericsson and Swedish Match in Switzerland.

Independency: Independent in relation to the company, its management and the company’s major shareholders.

Last updated: November 21, 2019


Member of the board since: 2019
Born: 1961
Education: PhD Biochemistry
Shares in Genovis: 5,160 shares

Other Directorship

Board member of Vinnova, SwedenBio, AmCham Sweden, Atlas Antibodies AB and several companies within the GE Group.

Relevant Work Experience

Currently employed as CEO of GE Nordics and the Testa Center in Uppsala. She is the former CEO of IMED AB and global head of BioProcess R&D at GEHC Life Science. She has also held several project management positions at Pharmacia Corp & Pharmacia & Upjohn.

Independency: Independent in relation to the company, its management and the company’s major shareholders.

Last updated: June 11, 2019

Member of the board since: 2019
Born: 1959
Education: BSc in International Business
Shares in Genovis: 5,500

Other Directorship

Board member of GHW Consulting AB and Beactica Therapeutics AB.

Relevant Work Experience

Currently runs his own consultancy firm and has 30 years of experience from international strategy formulation, business development and commercialization. Has held leading positions in international pharmaceutical and biotech companies, among others CBO and CEO of Lytix Biopharma as well as various management positions in AstraZeneca.

Independency: Independent in relation to the company, its management and the company’s major shareholders.

Last updated: Mar 23, 2020

  • Svenska